对已批准的糖尿病黄斑水肿药物随机对照试验长期结果的最新综述。

眼科学报 Pub Date : 2016-04-18 DOI:10.21037/JES.2016.04.12

Jiakui Wang, Tzu-Lun Huang, P. Su, P. Chang

{"title":"对已批准的糖尿病黄斑水肿药物随机对照试验长期结果的最新综述。","authors":"Jiakui Wang, Tzu-Lun Huang, P. Su, P. Chang","doi":"10.21037/JES.2016.04.12","DOIUrl":null,"url":null,"abstract":"Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. We review the long-term outcome of four approved pharmacotherapy for treating DME, including intravitreal injections of corticosteroids (dexamethasone implants and fluocinolone acetonide inserts) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular focal/grid laser treatment. Anti-VEGF agents result in low incidence of severe ocular or systemic adverse effects, but glaucoma and cataract should be aware after intravitreal corticosteroids. Prompt treatment with these agents can lead to a better outcome","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema.\",\"authors\":\"Jiakui Wang, Tzu-Lun Huang, P. Su, P. Chang\",\"doi\":\"10.21037/JES.2016.04.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. We review the long-term outcome of four approved pharmacotherapy for treating DME, including intravitreal injections of corticosteroids (dexamethasone implants and fluocinolone acetonide inserts) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular focal/grid laser treatment. Anti-VEGF agents result in low incidence of severe ocular or systemic adverse effects, but glaucoma and cataract should be aware after intravitreal corticosteroids. Prompt treatment with these agents can lead to a better outcome\",\"PeriodicalId\":12096,\"journal\":{\"name\":\"眼科学报\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"眼科学报\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/JES.2016.04.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/JES.2016.04.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

摘要

糖尿病性黄斑水肿(DME)是糖尿病患者视力威胁的主要原因。我们回顾了四种已批准的治疗二甲醚的药物治疗的长期结果，包括玻璃体内注射皮质类固醇(地塞米松植入物和氟西诺酮醋酸酯植入物)和抗血管内皮生长因子(VEGF)(雷尼单抗和阿非利西普)。与假注射或黄斑焦点/网格激光治疗相比，它们都表现出更好的改善视力和减少黄斑厚度的能力。抗vegf药物导致严重的眼部或全身不良反应的发生率较低，但玻璃体内皮质类固醇后应注意青光眼和白内障。及时使用这些药物治疗可以获得更好的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema.

Diabetic macular edema (DME) is a major sight-threatening cause in diabetic patients. We review the long-term outcome of four approved pharmacotherapy for treating DME, including intravitreal injections of corticosteroids (dexamethasone implants and fluocinolone acetonide inserts) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular focal/grid laser treatment. Anti-VEGF agents result in low incidence of severe ocular or systemic adverse effects, but glaucoma and cataract should be aware after intravitreal corticosteroids. Prompt treatment with these agents can lead to a better outcome

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

眼科学报

自引率

0.00%

发文量

1312

期刊介绍： Eye science was founded in 1985. It is a national medical journal supervised by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and hosted by Sun Yat-sen University Zhongshan Eye Center (in October 2020, it was changed from a quarterly to a monthly, with the publication number: ISSN: 1000-4432; CN: 44-1119/R). It is edited by Ge Jian, former dean of Sun Yat-sen University Zhongshan Eye Center, Liu Yizhi, director and dean of Sun Yat-sen University Zhongshan Eye Center, and Lin Haotian, deputy director of Sun Yat-sen University Zhongshan Eye Center, as executive editor. It mainly reports on new developments and trends in the field of ophthalmology at home and abroad, focusing on basic research in ophthalmology, clinical experience, and theoretical knowledge and technical operations related to epidemiology. It has been included in important databases at home and abroad, such as Chemical Abstract (CA), China Journal Full-text Database (CNKI), China Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Journal Database (VIP).